Latest revenue
$17.5K
as of 2024-06-30
Latest net income
$-2.3M
as of 2024-06-30
Net margin
-12986.0%
as of 2024-06-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think AXIM is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.5M
- Enterprise value
- $1.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.02
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 302.0M
5-year trend
What this company does
Overview Axim Biotechnologies, Inc., a Nevada corporation, is a leading developer of diagnostic healthcare solutions serving to enhance the health of people. Through the development of diagnostic solutions that quickly and accurately diagnose various diseases, our products allow healthcare workers to quickly test and treat at the point-of-care, which leads to improved patient outcomes and provides numerous economic benefits to the healthcare system. Axim’s core competencies include development of rapid lateral flow immunoassays, reagents and monoclonal antibody development for such assays. Our current products fall into these categories: (1) Eye Health, wherein we acquired two FDA cleared…
AI summary unavailable — showing raw filing excerpt
Generated from AXIM's filing dated 2024-04-16
Key risks
Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, operating results, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and…
AI summary unavailable — showing raw filing excerpt
Generated from AXIM's filing dated 2024-04-16
Profitability
Operating margin
-6961.0%
86.7%Net margin
-20395.0%
71.0%Return on equity
105.3%
18.6%Return on assets
-195.5%
31.9%Leverage
Debt / equity
-1.54×
17.9%Long-term debt / equity
-0.56×
37.1%Debt / assets
285.8%
33.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q2 2024 2024-06-30 | $17.5K | +76.0% | $-2.3M | +39.0% | -12986.0% |
Q1 2024 2024-03-31 | $53.0K | — | $-292.3K | — | -551.7% |
Q3 2023 2023-09-30 | $9.6K | — | $328.5K | — | 3428.3% |
Q2 2023 2023-06-30 | $9.9K | — | $-3.7M | — | -37499.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AXIM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for AXIM in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns AXIM
No institutional holdings on file for AXIM yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once AXIM's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.